Glycosyltransferase B4GALNT2 as a Predictor of Good Prognosis in Colon Cancer: Lessons from Databases

Background: glycosyltransferase B4GALNT2 and its cognate carbohydrate antigen Sda are highly expressed in normal colon but strongly downregulated in colorectal carcinoma (CRC). We previously showed that CRC patients expressing higher B4GALNT2 mRNA levels displayed longer survival. Forced B4GALNT2 expression reduced the malignancy and stemness of colon cancer cells. Methods: Kaplan–Meier survival curves were determined in “The Cancer Genome Atlas” (TCGA) COAD cohort for several glycosyltransferases, oncogenes, and tumor suppressor genes. Whole expression data of coding genes as well as miRNA and methylation data for B4GALNT2 were downloaded from TCGA. Results: the prognostic potential of B4GALNT2 was the best among the glycosyltransferases tested and better than that of many oncogenes and tumor suppressor genes; high B4GALNT2 expression was associated with a lower malignancy gene expression profile; differential methylation of an intronic B4GALNT2 gene position and miR-204-5p expression play major roles in B4GALNT2 regulation. Conclusions: high B4GALNT2 expression is a strong predictor of good prognosis in CRC as a part of a wider molecular signature that includes ZG16, ITLN1, BEST2, and GUCA2B. Differential DNA methylation and miRNA expression contribute to regulating B4GALNT2 expression during colorectal carcinogenesis.

[1]  Chun-hui Jiang,et al.  Identification and development of a novel invasion-related gene signature for prognosis prediction in colon adenocarcinoma , 2021, Cancer cell international.

[2]  H. Meng,et al.  ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer , 2020, Translational oncology.

[3]  M. Ferracin,et al.  The Sda Synthase B4GALNT2 Reduces Malignancy and Stemness in Colon Cancer Cell Lines Independently of Sialyl Lewis X Inhibition , 2020, International journal of molecular sciences.

[4]  M. Ferracin,et al.  High Expression of the Sda Synthase B4GALNT2 Associates with Good Prognosis and Attenuates Stemness in Colon Cancer , 2020, Cells.

[5]  L. Qin,et al.  Application of weighted gene co-expression network analysis to explore the potential diagnostic biomarkers for colorectal cancer , 2020, Molecular medicine reports.

[6]  Zhitong Bing,et al.  Integrative Gene Expression Profiling Analysis to Investigate Potential Prognostic Biomarkers for Colorectal Cancer , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[7]  Kyoko Kojima‐Aikawa,et al.  ZG16p, an Animal Homologue of Plant β-Prism Fold Lectins: Purification Methods of Natural and Recombinant ZG16p and Inhibition Assay of Cancer Cell Growth Using ZG16p. , 2020, Methods in molecular biology.

[8]  M. Ferracin,et al.  Impact of sialyltransferase ST6GAL1 overexpression on different colon cancer cell types. , 2019, Glycobiology.

[9]  G. Larson,et al.  Missense mutations in the C-terminal portion of the B4GALNT2-encoded glycosyltransferase underlying the Sd(a−) phenotype , 2019, Biochemistry and biophysics reports.

[10]  N. Mokhtar,et al.  Colonic Mucosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Pathways , 2019, Journal of Crohn's & colitis.

[11]  L. Héliot,et al.  The extended cytoplasmic tail of the human B4GALNT2 is critical for its Golgi targeting and post‐Golgi sorting , 2018, The FEBS journal.

[12]  K. Katakura,et al.  Glycosyltransferase Gene Expression Identifies a Poor Prognostic Colorectal Cancer Subtype Associated with Mismatch Repair Deficiency and Incomplete Glycan Synthesis , 2018, Clinical Cancer Research.

[13]  Liang Wang,et al.  Loss of ZG16 is associated with molecular and clinicopathological phenotypes of colorectal cancer , 2018, BMC Cancer.

[14]  Clement Adebamowo,et al.  Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context , 2018, Cell reports.

[15]  Nobuo Sasaki,et al.  Lectin ZG16p inhibits proliferation of human colorectal cancer cells via its carbohydrate-binding sites , 2018, Glycobiology.

[16]  Kazuhiro Yoshida,et al.  Adiponectin and Intelectin-1: Important Adipokine Players in Obesity-Related Colorectal Carcinogenesis , 2017, International journal of molecular sciences.

[17]  Ajit Varki,et al.  Biological roles of glycans , 2016, Glycobiology.

[18]  B. Jung,et al.  Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer. , 2017, Gastroenterology.

[19]  S. Waldman,et al.  Guanylyl cyclase C signaling axis and colon cancer prevention , 2016, World journal of gastroenterology.

[20]  J. Costello,et al.  Cancer: Oncogene brought into the loop , 2015, Nature.

[21]  S. Pinho,et al.  Glycosylation in cancer: mechanisms and clinical implications , 2015, Nature Reviews Cancer.

[22]  Qingtao Meng,et al.  Knockdown of ST6Gal-I inhibits the growth and invasion of osteosarcoma MG-63 cells. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[23]  R. Jorissen,et al.  Defective Myb Function Ablates Cyclin E1 Expression and Perturbs Intestinal Carcinogenesis , 2015, Molecular Cancer Research.

[24]  Y. Rombouts,et al.  Glycosylation characteristics of colorectal cancer. , 2015, Advances in cancer research.

[25]  R. Kannagi,et al.  Therapeutic adenoviral gene transfer of a glycosyltransferase for prevention of peritoneal dissemination and metastasis of gastric cancer , 2014, Cancer Gene Therapy.

[26]  F. dall’Olio,et al.  Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. , 2014, Biochimica et biophysica acta.

[27]  F. dall’Olio,et al.  The expanding roles of the Sd(a)/Cad carbohydrate antigen and its cognate glycosyltransferase B4GALNT2. , 2014, Biochimica et biophysica acta.

[28]  F. dall’Olio,et al.  The expanding roles of the Sda / Cad carbohydrate antigen and its cognate glycosyltransferase B 4 GALNT 2 , 2013 .

[29]  F. Bäckhed,et al.  Expression of the blood-group-related glycosyltransferase B4galnt2 influences the intestinal microbiota in mice , 2012, The ISME Journal.

[30]  F. dall’Olio,et al.  Mechanisms of cancer-associated glycosylation changes. , 2012, Frontiers in bioscience.

[31]  M. Toyota,et al.  DNA hypermethylation contributes to incomplete synthesis of carbohydrate determinants in gastrointestinal cancer. , 2008, Gastroenterology.

[32]  Lung-Chih Yu,et al.  Expression of the human Sd(a) beta-1,4-N-acetylgalactosaminyltransferase II gene is dependent on the promoter methylation status. , 2007, Glycobiology.

[33]  D. Santini,et al.  Biosynthesis and expression of the Sda and sialyl Lewis x antigens in normal and cancer colon. , 2007, Glycobiology.

[34]  B. Xia,et al.  Increased susceptibility to colitis and colorectal tumors in mice lacking core 3–derived O-glycans , 2007, The Journal of experimental medicine.

[35]  Toshio Shimizu,et al.  Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis. , 2005, Cancer research.

[36]  Mariella Chiricolo,et al.  Molecular cloning of the human beta1,4 N-acetylgalactosaminyltransferase responsible for the biosynthesis of the Sd(a) histo-blood group antigen: the sequence predicts a very long cytoplasmic domain. , 2003, Journal of biochemistry.

[37]  P. Delannoy,et al.  Molecular cloning, gene organization and expression of the human UDP-GalNAc:Neu5Acalpha2-3Galbeta-R beta1,4-N-acetylgalactosaminyltransferase responsible for the biosynthesis of the blood group Sda/Cad antigen: evidence for an unusual extended cytoplasmic domain. , 2003, The Biochemical journal.

[38]  M. Tsujimoto,et al.  Characterization of the Second Type of Human β-Galactoside α2,6-Sialyltransferase (ST6Gal II), Which Sialylates Galβ1,4GlcNAc Structures on Oligosaccharides Preferentially , 2002, The Journal of Biological Chemistry.

[39]  M. Tsujimoto,et al.  Characterization of the second type of human beta-galactoside alpha 2,6-sialyltransferase (ST6Gal II), which sialylates Galbeta 1,4GlcNAc structures on oligosaccharides preferentially. Genomic analysis of human sialyltransferase genes. , 2002, The Journal of biological chemistry.

[40]  Y. Kim,et al.  Sd(a)-antigen-like structures carried on core 3 are prominent features of glycans from the mucin of normal human descending colon. , 2001, The Biochemical journal.

[41]  A. Bardoni,et al.  β1,3-Galactosyltransferase β3Gal-T5 Acts on the GlcNAcβ1→3Galβ1→4GlcNAcβ1→R Sugar Chains of Carcinoembryonic Antigen and Other N-Linked Glycoproteins and Is Down-regulated in Colon Adenocarcinomas* , 2001, The Journal of Biological Chemistry.

[42]  C. Belluco,et al.  Clinical Correlations of α2,6-Sialyltransferase Expression in Colorectal Cancer Patients , 2000 .

[43]  下平 和久.  Carcinoma-associated expression of core 2 β-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer : role of O-glycans in tumor progression , 1999 .

[44]  J. Lowe,et al.  Molecular cloning of a murine N-acetylgalactosamine transferase cDNA that determines expression of the T lymphocyte-specific CT oligosaccharide differentiation antigen. , 1994, The Journal of biological chemistry.

[45]  F. Minni,et al.  Expression of UDP-GalNAc:NeuAcα2,3Galβ-R β1,4(GalNAc to Gal) N-Acetylgalactosaminyltransferase Involved in the Synthesis of Sda Antigen in Human Large Intestine and Colorectal Carcinomas , 1989 .

[46]  F. Minni,et al.  Increased CMP‐NeuAc:Galβ1,4GlcNAc‐R α2,6 sialyltransferase activity in human colorectal cancer tissues , 1989 .

[47]  K. McEntee,et al.  Primary structure of beta-galactoside alpha 2,6-sialyltransferase. Conversion of membrane-bound enzyme to soluble forms by cleavage of the NH2-terminal signal anchor. , 1987, The Journal of biological chemistry.

[48]  F. dall’Olio,et al.  Guinea-pig kidney beta-N-acetylgalactosaminyltransferase towards Tamm-Horsfall glycoprotein. Requirement of sialic acid in the acceptor for transferase activity. , 1983, The Biochemical journal.